Repros Therapeutics Inc. is expected to report third-quarter 2016 results on Nov 14. The company has reported an average positive surprise of 24.56% in the last two quarters. Let’s see how things are shaping up for this quarter.
Factors at Play
Repros is a development-stage biotech company focused on the development of treatments for hormonal and reproductive system disorders. With no approved products in its portfolio yet, investors are expected to keep an eye on pipeline-related updates by the company. Repros’ pipeline presently comprises enclomiphene and Proellex.
The most advanced candidate in Repros’ pipeline is enclomiphene, which is currently under review in the EU. The company is looking to get the candidate approved for the treatment of secondary hypogonadism. A decision on the approval status of the candidate should be out in 2017.
Meanwhile, Repros is conducting a placebo-controlled, double-blind, proof-of-concept phase II study (ZA-205) on enclomiphene in obese secondary hypogonadal men to assess its impact on metabolic parameters and quality of life with a routine diet and exercise. Six-month interim data from the study were reported in Aug 2016.
Also, Repros plans to hold a discussion with the FDA regarding the prospects of advancing Proellex into phase III studies for the treatment of women struggling with painful menstruation. In addition, Proellex is being evaluated for the treatment of uterine fibroids.
Repros currently carries a Zacks Rank #3 (Hold).
Stocks that Warrant a Look
Here are some companies in the health care sector you may want to consider as our model shows that they have the right combination of elements – a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 – to post an earnings beat this quarter.
ARIAD Pharmaceuticals Inc. is expected to release results on Nov 7. The company has an Earnings ESP of 5.26% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
ACADIA Pharmaceuticals Inc. (ACAD - Free Report) is scheduled to release results on Nov 7. The company has an Earnings ESP of 5.46% and a Zacks Rank #1.
Synergy Pharmaceuticals Inc (SGYP - Free Report) is expected to release results on Nov 14. The company has Earnings ESP of 18.18% and a Zacks Rank #3.
Please check our Earnings ESP Filter that enables you to find stocks that are expected to come out with earnings surprises.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>